Table 3.
Brain metastases treatment.
| Reference | Median Survival in Months (range) a | Surgery (%) | Radiation (%) | Surgery and Radiation (%) | Supportive Care (%) | Other (%) | Type of Radiation Therapy |
|---|---|---|---|---|---|---|---|
| Myint ZW 2021 [4] | 12 | 19 | 13 | ||||
| Boxley PJ 2021 [5] | |||||||
| Bhambhvani HP 2020 [11] | 3 (0.4–25) | 42 | 26 | 32 | SRS | ||
| Nguyen T 2020 [12] | 2 | 100 | WBRT | ||||
| Ganau M 2020 [40] | 100 | WBRT, SRS | |||||
| Ormond DR 2019 [46] | |||||||
| Zhao F 2019 [44] | 10 | ||||||
| Kanyılmaz G 2019 [13] | 4.5 (2–21) | 100 | WBRT | ||||
| Hatzoglou V 2014 [38] | 2.8 | ||||||
| Bartscht T 2014 [30] | 100 | WBRT | |||||
| Gzell CE 2013 [39] | 3.5 (2–24+) | 25 | 75 | WBRT | |||
| Caffo O 2013 [7] | 2 (0.25–35.4) | ||||||
| Caffo O 2012 [47] | 4 | 3 | 32 | 16 | 48 | 35 | WBRT, SRS |
| Guedes B 2011 [37] | |||||||
| Lawton A 2010 [45] | 6.17 (<1–15) | 70 | 20 | 30 | |||
| Flannery T 2010 [31] | 13 | 100 | SRS | ||||
| Lin C 2008 [10] | 75 | 25 | WBRT | ||||
| Kim SH 2008 [32] | 7 (6–22+) | 80 | 20 | WBRT, SRS | |||
| Salvati M 2005 [9] | 13 | 23 | 77 | 8 | WBRT, SRS | ||
| Tremont-Lukats IW 2003 [14] | 1 | 24 | 76 | SRS | |||
| McCutcheon IE 1999 [34] | 4 | 3 | 76 | 21 | WBRT | ||
| Nussbaum ER 1996 [36] | 13 | ||||||
| Chung TS 1986 [42] | 7.6 (mean) | 71 | 29 | WBRT | |||
| Taylor HG 1984 [33] | |||||||
| Castaldo JE 1983 [43] | 7 | 50 | 50 | WBRT | |||
| Sarma DP 1983 [35] | 25 | ||||||
| Catane R 1976 [41] | 40 | WBRT | |||||
| # Studies Reporting | 4.5 (median) | 5 | 15 | 7 | 7 | 4 | N/A |
SRS: stereotactic radiosurgery and WBRT: whole-brain radiotherapy. Cells were left blank when this information was not reported in the article. a Median survival time from brain metastasis diagnosis (Salvati et al. and Castaldo et al. reported individual patient survival information, which was used to calculate a median survival of 13 and 7 months, respectively, by Kaplan–Meier analysis).